Related Experiment Videos
Class A beta-lactamases--enzyme-inhibitor interactions and resistance
Y Yang1, B A Rasmussen, D M Shlaes
1Wyeth-Ayerst Research, Pearl River, NY 10965, USA.
Pharmacology & Therapeutics
|October 8, 1999
Summary
Class A beta-lactamase inhibitors like clavulanic acid and penicillanic acid sulfones combat bacterial resistance. Specific mutations in these enzymes can confer resistance, impacting inhibitor effectiveness differently based on the inhibitor type.
Area of Science:
- Biochemistry
- Microbiology
- Drug Resistance
Background:
- Ambler's Class A beta-lactamases are a primary cause of bacterial resistance to beta-lactam antibiotics.
- Evolution of resistance occurs through mutations in beta-lactamase genes, driven by antibiotic selective pressure.
- Clinical use of beta-lactamase inhibitors includes clavulanic acid, sulbactam, and tazobactam.
Purpose of the Study:
- To review the inhibition mechanisms of current beta-lactamase inhibitors.
- To elucidate how specific amino acid substitutions lead to inhibitor resistance.
- To differentiate resistance mechanisms against clavulanic acid versus penicillanic acid sulfones.
Main Methods:
- Focus on reviewing existing literature on beta-lactamase inhibition.
- Analysis of key amino acid positions (Met69, Ser130, Arg244, Arg275, Asn276) involved in resistance.
- Examination of site-directed mutagenesis studies to confirm enzyme roles.
Main Results:
- Ser130 is crucial for the chemical inhibition mechanism.
- Arg244, Arg275, and Asn276 form hydrogen bonds, with Arg244 positioning beta-lactams and inhibitors.
- Proton donation is essential for clavulanic acid inactivation but not for sulfone inhibitors, leading to differential resistance effects.
Conclusions:
- Amino acid substitutions can confer resistance to beta-lactamase inhibitors.
- The mechanism of resistance varies between clavulanic acid and penicillanic acid sulfones.
- Understanding these resistance mechanisms is vital for developing effective antibiotic therapies.